Leon Recanati Biography and Net Worth

Director of Evogene

Mr. Leon Y. Recanati has served as Evogene director since 2005. Mr. Recanati has served as chairman and chief executive officer of GlenRock Israel Ltd., his private investment company, investing since 2003 in Venture Capital and private equity companies. Previously, Mr. Recanati was chief executive officer and/or chairman of IDB Holding Corporation; Clal Industries Ltd.; Azorim Investment Development and Construction Co Ltd.; Delek Israel Fuel Corporation; and Super-Sol Ltd. He also founded Clal Biotechnologies Industries Ltd., a biotechnology investment company operating in Israel.

Mr. Recanati is a member of the board of directors of Kamada, Ofil Systems, and Shavit Capital. He is active in education and health endeavors through several NGO’s, Chair of MadaTech Israel National museum of Science Technology and Space, Vice Chair of Israel Cancer Association.

Mr. Recanati holds an MBA from the Hebrew University of Jerusalem and Honorary Doctorates from the Technion Institute of Technology and Tel Aviv University.

What is Leon Recanati's net worth?: The estimated net worth of Leon Recanati is at least $535.54 thousand as of August 11th, 2026. Mr. Recanati owns 1,343,886 shares of Evogene stock worth more than $535,539 as of October 9th. This net worth approximation does not reflect any other assets that Mr. Recanati may own. Learn More about Leon Recanati's net worth.
How do I contact Leon Recanati?: The corporate mailing address for Mr. Recanati and other Evogene executives is 13 Gad Feinstein Street, Rehovot, HM, 7638517. Evogene can also be reached via phone at (728) 931-1900 and via email at [email protected]. Learn More on Leon Recanati's contact information.
Has Leon Recanati been buying or selling shares of Evogene?: Leon Recanati has not been actively trading shares of Evogene during the past quarter. Most recently, on Tuesday, August 11th, Leon Recanati bought 460,000 shares of Evogene stock. The stock was acquired at an average cost of $0.64 per share, with a total value of $294,400.00. Following the completion of the transaction, the director now directly owns 1,343,886 shares of the company's stock, valued at $860,087.04. Learn More on Leon Recanati's trading history.
Are insiders buying or selling shares of Evogene?: In the last twelve months, Evogene insiders bought shares 1 times. They purchased a total of 460,000 shares worth more than $294,400.00. The most recent insider tranaction occured on August, 11th when Director Leon Recanati bought 460,000 shares worth more than $294,400.00. Insiders at Evogene own 7.4% of the company. Learn More about insider trades at Evogene.
Information on this page was last updated on 8/11/2026.

Leon Recanati Insider Trading History at Evogene

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/11/2026	Buy	460,000	$0.64	$294,400.00	1,343,886

Leon Recanati Buying and Selling Activity at Evogene

Evogene Company Overview

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Today's Range

Now: $0.39

$0.39

50 Day Range

MA: $0.52

$0.38

$0.70

2 Week Range

Now: $0.39

$0.35

$1.49

Volume

4,015 shs

Average Volume

1,170,667 shs

Market Capitalization

$3.37 million

P/E Ratio

N/A

Dividend Yield